These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 25670042

  • 1. VEGF-D and A Preoperative Serum Levels Predict Nodal and Distant Metastases in Differentiated Thyroid Cancer Patients.
    Lai CW, Duh QY, Chen CW, Chuang FJ, Chang YJ, Lin MT, Wu MH.
    World J Surg; 2015 Jul; 39(7):1742-9. PubMed ID: 25670042
    [Abstract] [Full Text] [Related]

  • 2. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma.
    Yu XM, Lo CY, Lam AK, Leung P, Luk JM.
    Ann Surg; 2008 Mar; 247(3):483-9. PubMed ID: 18376194
    [Abstract] [Full Text] [Related]

  • 3. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation.
    Tuttle RM, Fleisher M, Francis GL, Robbins RJ.
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1737-42. PubMed ID: 11932308
    [Abstract] [Full Text] [Related]

  • 4. Serum vascular endothelial growth factor-D levels correlate with cervical lymph node metastases in papillary thyroid carcinoma.
    Lai CW, Chen KY, Hung CS, Kuo SW, Chang YJ, Lin MT, Chang KC, Wu MH.
    Growth Factors; 2011 Apr; 29(2-3):57-62. PubMed ID: 21319951
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
    Lima N, Cavaliere H, Tomimori E, Knobel M, Medeiros-Neto G.
    J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
    [Abstract] [Full Text] [Related]

  • 6. VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma.
    Karaca Z, Tanriverdi F, Unluhizarci K, Ozturk F, Gokahmetoglu S, Elbuken G, Cakir I, Bayram F, Kelestimur F.
    Eur J Endocrinol; 2011 Feb; 164(2):277-84. PubMed ID: 21097568
    [Abstract] [Full Text] [Related]

  • 7. Lymph nodes metastases in differentiated thyroid cancer--prognostic value and surgical results with 430 patients for 30 years period (1980-2010).
    Petkov R, Katev N, Todorov G, Mladenovski V, Yaramov N, Sokolov M.
    Khirurgiia (Sofiia); 2011 Feb; (1):5-11. PubMed ID: 23847796
    [Abstract] [Full Text] [Related]

  • 8. Predicting lymph node metastasis in patients with papillary thyroid carcinoma by vascular index on power Doppler ultrasound.
    Lee JH, Shin HJ, Yoon JH, Kim EK, Moon HJ, Lee HS, Kwon HJ, Kwak JY.
    Head Neck; 2017 Feb; 39(2):334-340. PubMed ID: 27704649
    [Abstract] [Full Text] [Related]

  • 9. [The significance of lymph node status in papillary and follicular thyroid gland carcinoma for the nuclear medicine physician].
    Farahati J, Mörtl M, Reiners C.
    Zentralbl Chir; 2000 Feb; 125(10):830-4. PubMed ID: 11098578
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prognostic factors associated with differentiated thyroid cancer.
    Tsuchiya A, Suzuki S, Kanno M, Kikuchi Y, Ando Y, Abe R.
    Surg Today; 1995 Feb; 25(9):778-82. PubMed ID: 8555694
    [Abstract] [Full Text] [Related]

  • 12. [Lymph node dissection in non-medullary differentiated thyroid carcinoma].
    Mathonnet M.
    Ann Chir; 2006 Feb; 131(6-7):361-8. PubMed ID: 16329987
    [Abstract] [Full Text] [Related]

  • 13. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer.
    Lin SY, Wang YY, Sheu WH.
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):513-8. PubMed ID: 12641636
    [Abstract] [Full Text] [Related]

  • 14. [Significance of lymph node metastases of differentiated thyroid gland carcinomas and C-cell carcinomas for prognosis--a meta-analysis].
    Witte J, Schlotmann U, Simon D, Dotzenrath C, Ohmann C, Goretzki PE.
    Zentralbl Chir; 1997 Apr; 122(4):259-65. PubMed ID: 9221636
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients.
    Mercante G, Frasoldati A, Pedroni C, Formisano D, Renna L, Piana S, Gardini G, Valcavi R, Barbieri V.
    Thyroid; 2009 Jul; 19(7):707-16. PubMed ID: 19348581
    [Abstract] [Full Text] [Related]

  • 17. Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma.
    Hsueh C, Lin JD, Wu IC, Chao TC, Yu JS, Liou MJ, Yeh CJ.
    J Surg Oncol; 2011 Apr; 103(5):395-9. PubMed ID: 21400522
    [Abstract] [Full Text] [Related]

  • 18. Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.
    Mariotti S, Barbesino G, Caturegli P, Marinò M, Manetti L, Fugazzola L, Pacini F, Pinchera A.
    J Endocrinol Invest; 1994 Dec; 17(11):861-7. PubMed ID: 7745234
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin.
    Westbury C, Vini L, Fisher C, Harmer C.
    Thyroid; 2000 Feb; 10(2):171-6. PubMed ID: 10718555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.